

# FAVIPIRAVIR - PATENT ANALYSIS REPORT



**CAS Number:** 259793-96-9

**Synonyms:** T-705, 6-fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide

**Innovator/Originator:** Toyama Chemical (Fujifilm group)

**Brand Name:** Avigan


**Pharmaceutical form & strength:** Oral tablet formulation, 200MG

**Marketing authorisation holder:** Fujifilm Corporation

**Marketing Status:** Authorised in Japan

**Approval Date:** March 2014

**Approved Therapeutic Indication:** Infectious disease; Influenza virus infection



On March 31, Fujifilm announced the start of a phase III clinical trial of Avigan for **COVID-19 patients in Japan.**

Fujifilm announces the start of a phase II clinical trial of its influenza antiviral drug “Avigan® Tablet” for **COVID-19 patients in the U.S** on April 9, 2020.

